Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 3

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 2(2)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07565701Phase 3Not Yet Recruiting

Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis

Role: collaborator

NCT07086755Phase 2Recruiting

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

Role: collaborator

NCT04478071Phase 2Completed

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Role: collaborator

NCT04922645Phase 4Completed

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

Role: collaborator

All 4 trials loaded